The government has virtually expressed opposition to the National Assembly and the pharmaceutical industry's demand to exclude PVA from innovative development drugs.

PVA is a system that shares the burden of health insurance spending between health insurance financial authorities and pharmaceutical companies, and the government explains that if only certain drugs are provided with preferential treatment, equity issues are concerned.

On the 1st, the MOHW explained as follows when Rep. Seo Jung-sook and Rep. Kang Ki-yoon of the People Power Party of the National Assembly Health and Welfare Committee pointed out.

The National Assembly and the domestic pharmaceutical industry